➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Mallinckrodt
AstraZeneca
Medtronic
Baxter

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 4,981,791

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 4,981,791
Title: RNA stabilization vector
Abstract:The present invention provides an RNA stabilization vector including a cloning vehicle, a group I intron inserted into the cloning vehicle and foreign DNA inserted into the intron. The present invention further provides a method for enhancing the production of a gene product by stabilizing the mRNA coding for the gene product using the RNA stabilization vector.
Inventor(s): Belfort; Marlene (Slingerlands, NY)
Assignee: Health Research Incorporated (Albany, NY)
Application Number:07/211,594
Patent Claims:1. An RNA stabilization vector, which comprises:

a cloning vehicle;

a group I intron inserted into the cloning vehicle; and

foreign DNA inserted into the intron the resulting foreign DNA-intron fusion not being found in nature.

2. An RNA stabilization vector as in claim 1, wherein the cloning vehicle is a bacterial cloning vehicle.

3. An RNA stabilization vector as in claim 2, wherein the bacterial cloning vehicle is a plasmid.

4. An RNA stabilization vector as in claim 1, wherein the group I intron is the td gene of bacteriophage T4.

5. An RNA stabilization vector as in claim 4, wherein the td gene of bacteriophage T4 is modified by deleting a portion of the intron not contributing to group I secondary structure of the intron.

6. An RNA stabilization vector as in claim 1, wherein the intron is located downstream of a promoter for expressing the foreign DNA.

7. An RNA stabilization vector as in claim 1, further comprising a different restriction enzyme insertion site within the intron.

8. An RNA stabilization vector as in claim 3, wherein the plasmid is pUC9.

9. An RNA stabilization vector as in claim 3, wherein the plasmid is pKK223-3.

10. A method for producing a vector for stabilizing mRNA coding for a gene product, which method comprises inserting a foreign gene coding for the gene product into a group I intron in a cloning vehicle the resulting foreign gene-intron fusion not being found in nature.

11. A method for enhancing the production of a gene product, which comprises:

inserting a foreign gene into a group I intron in a cloning vehicle the resulting foreign gene-intron fusion not being found in nature;

transcribing the intron with inserted foreign gene in a host cell to form a foreign gene-intron RNA fusion; and

translating the foreign gene-intron RNA fusion in the host cell to form the gene product of the foreign gene.

12. A method as in claim 11, wherein the cloning vehicle is a bacterial cloning vehicle.

13. A method as in claim 12, wherein the bacterial cloning vehicle is a plasmid.

14. A method as in claim 11, wherein the group I intron is a td gene of bacteriophage T4.

15. A method as in claim 14, wherein the td gene of bacteriophage T4 is modified by deleting a portion of the intron not contributing to group I secondary structure of the intron.

Details for Patent 4,981,791

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ⤷  Free Forever Trial Health Research Incorporated (Albany, NY) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ⤷  Free Forever Trial Health Research Incorporated (Albany, NY) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ⤷  Free Forever Trial Health Research Incorporated (Albany, NY) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKinsey
Boehringer Ingelheim
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.